title: Effect of pituitary adenylate cyclase-activating polypeptide on exocrine and endocrine secretion in the ovine pancreas.
abstract: The role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the regulation of exocrine and endocrine pancreas was investigated in conscious sheep. Intravenous infusions of PACAP-27 and PACAP-38 (1, 3, and 10 pmol/kg/min) for 10 min during phase II of the duodenal migrating myoelectric complex accelerated pancreatic protein and amylase outputs dose-dependently. The responses in enzyme secretion to both PACAPs at the highest doses were inhibited significantly by atropine infusion (14.4 nmol/kg/min). Vasoactive intestinal polypeptide (VIP) at 3 pmol/kg/min significantly accelerated protein but not amylase outputs, although the response to the highest dose was not significantly influenced by atropine. PACAP-27 and VIP increased pancreatic juice flow and bicarbonate output dose-dependently; however, the responses to the highest dose were not altered significantly by atropine. On the other hand, intravenous injection of PACAP-38 (100 pmol/kg) did not influence basal plasma concentration of insulin, glucagon, and glucose. Moreover, PACAP-38 (1-100 pmol/kg) altered neither pancreatic endocrine response to intravenous infusion of glucose (20 mumol/kg/min) not that to n-butyric acid (33 mumol/kg/min). These results suggest that PACAP contributes to the regulation of exocrine secretion of the ovine pancreas but not to endocrine secretion. PACAP appears to accelerate pancreatic enzyme secretion mostly via the cholinergic nerves.
authors.affiliation: Department of Veterinary Medicine, Rakuno Gakuen University, Hokkaido, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Onaga
authors.forename: M
authors.initials: M
authors.lastname: Uchida
authors.forename: M
authors.initials: M
authors.lastname: Kimura
authors.forename: M
authors.initials: M
authors.lastname: Miyazaki
authors.forename: H
authors.initials: H
authors.lastname: Mineo
authors.forename: S
authors.initials: S
authors.lastname: Kato
authors.forename: R
authors.initials: R
authors.lastname: Zabielski
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002087:Butyrates / Q000494:pharmacology; D020148:Butyric Acid; D005934:Glucagon / Q000097:blood; D006633:Histamine Antagonists / Q000494:pharmacology; D007262:Infusions, Intravenous; D007328:Insulin / Q000097:blood; D008297:Male; D009479:Neuropeptides / Q000008:administration & dosage / Q000502:physiology*; D018377:Neurotransmitter Agents / Q000008:administration & dosage / Q000502:physiology*; D010179:Pancreas / Q000378:metabolism*; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D012756:Sheep; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage / Q000502:physiology*
chemical_list: D001786:Blood Glucose; D002087:Butyrates; D006633:Histamine Antagonists; D007328:Insulin; D009479:Neuropeptides; D018377:Neurotransmitter Agents; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D020148:Butyric Acid; D014660:Vasoactive Intestinal Peptide; D005934:Glucagon